EU: More Inspections and GMP Non-Compliance Statements
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
Register now for ECA's GMP Newsletter
The EU GMP inspectorates inspected more drug manufacturing facilities in 2017, according to the 2017 Annual Report from the European Medicines Agency (EMA). Also more inspections are now performed in the EU. Last year 2.122 inspections were conducted by EEA authorities in the EU/EEA (1.956 in 2016) and seven GMP Non-Compliance Statements were issued (five in 2016). Altogether, 2.493 inspections were performed worldwide (2.293 in 2016) leading to 17 GMP Non-Compliance Statements.
On the other hand, according the report, "the number of GMP inspections requests within the context of centralised marketing procedure declined in 2017". This decrease also reflects the implementation of the EU-US MRA. With this agreement, the equivalence of supervisory standards are recognised, inspection reports of the FDA can be accepted and inspections on each other's territories are reduced.
Source: European Medicines Agency Annual Report 2017.
Related GMP News
04.12.2024Discarded Batch Documentation again found during Inspection
30.10.2024From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
23.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
23.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?